Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva expects to more than double its respiratory sales to $2.4 billion by 2015, and launch multiple products in the timeframe, including an Advair-like product.
Advertisement

Related Content

Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
Teva Changes Its Tune On Substitutable Generic Advair
Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent
With LABA Safety Under Fire, Novartis Addresses Post-Market Studies
Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs
GSK Boosts Stake In Theravance, An Apparent Nod To The Biotech's Respiratory Portfolio
Vectura Pursues U.S. Partner For Inhaled Respiratory Therapy - A Generic Advair?
Respiratory Generics: Big Potential But A Tough Market To Crack
Respiratory Generics: Big Potential But A Tough Market To Crack

Topics

Advertisement
UsernamePublicRestriction

Register

PS071528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel